Daily Sepsis Research Analysis
Three papers advance sepsis science across mechanistic, translational, and prognostic fronts: (1) cardiomyocyte membrane cholesterol loss underlies sepsis-induced cardiomyopathy and is reversible by cholesterol infusion; (2) quorum sensing via Agr regulates phenol-soluble modulins driving mortality in Staphylococcus haemolyticus sepsis, spotlighting antivirulence targets; (3) a NETs-based transcriptomic score robustly predicts adverse outcomes in neonatal sepsis and links NETosis to coagulopathy
Summary
Three papers advance sepsis science across mechanistic, translational, and prognostic fronts: (1) cardiomyocyte membrane cholesterol loss underlies sepsis-induced cardiomyopathy and is reversible by cholesterol infusion; (2) quorum sensing via Agr regulates phenol-soluble modulins driving mortality in Staphylococcus haemolyticus sepsis, spotlighting antivirulence targets; (3) a NETs-based transcriptomic score robustly predicts adverse outcomes in neonatal sepsis and links NETosis to coagulopathy.
Research Themes
- Sepsis-induced cardiomyopathy and membrane lipid biology
- Quorum-sensing and antivirulence targets in coagulase-negative staphylococcal sepsis
- NETosis-driven coagulopathy and neonatal sepsis risk stratification
Selected Articles
1. Sepsis-induced hypocholesterolemia is linked to low cardiomyocyte membrane cholesterol and impaired catecholamine responsiveness.
Translational data link sepsis-induced hypocholesterolemia to reduced cardiomyocyte membrane cholesterol and impaired β-adrenergic inotropy. In a rat fecal peritonitis model mirroring ICU patients, cholesterol infusion (HDL or liposomal) restored membrane cholesterol, adrenergic signaling, and dobutamine responsiveness.
Impact: Identifies a modifiable biophysical mechanism for sepsis-induced cardiomyopathy and demonstrates pharmacologic reversibility, opening a testable therapeutic avenue.
Clinical Implications: Suggests investigating cholesterol/HDL-based strategies to restore inotropic responsiveness in sepsis-induced cardiomyopathy; supports lipid profiling as a prognostic adjunct. Human interventional trials are warranted before clinical adoption.
Key Findings
- In septic patients and rats, early decreases in plasma HDL-cholesterol correlated with worse outcomes.
- Cardiomyocyte membrane cholesterol decreased in septic rats, especially in poor-prognosis animals, with blunted dobutamine inotropy.
- Cholesterol infusion (HDL or liposomal) restored membrane cholesterol, β-adrenergic signaling, and dobutamine responsiveness.
Methodological Strengths
- Parallel human cohort and mechanistic animal model with convergent endpoints
- Interventional rescue experiment directly testing causality (cholesterol infusion)
Limitations
- Therapeutic reversal shown only in animals; no human interventional data
- Small human cohort (n=27) and potential confounding in observational comparisons
Future Directions: Pilot randomized trials testing HDL/cholesterol augmentation in sepsis-induced cardiomyopathy; mechanistic mapping of receptor–membrane lipid interactions and safety profiling.
BACKGROUND: Sepsis-induced cardiomyopathy (SIM) is characterized by myocardial dysfunction, diminished catecholamine responsiveness and worse outcomes. Hypocholesterolemia is also a well-recognized prognosticator of poor outcomes in sepsis. In vitro physiology/pharmacology studies indicate that low cholesterol levels within the cardiomyocyte membrane regulate ß-adrenergic receptor activity. We therefore hypothesized that cardiomyocyte membrane cholesterol levels are reduced in sepsis and this contributes to SIM. METHODS: Cardiovascular biomarkers and plasma lipid profiles measured sequentially (6, 24 and 72 h) in a fluid-resuscitated rat model of fecal peritonitis were compared against those measured in 27 septic patients on Days 1-3 of ICU admission. In separate studies, rat hearts were excised at the same time points for measurement of cardiomyocyte membrane cholesterol and downstream adrenergic signaling. In a final study, the impact of a 15-hour infusion of cholesterol, either given as HDL-cholesterol or liposomal cholesterol, commencing at 6 h post-sepsis induction, on dobutamine responsiveness and cardiomyocyte membrane cholesterol levels was assessed. RESULTS: The magnitude of fall in stroke volume, rise in heart rate, plasma troponin and BNP, and fall in plasma HDL-cholesterol on ICU Day 1 in septic patients and at 6 h in the rat model all prognosticated for poor outcomes. In parallel, cardiomyocyte membrane cholesterol fell in the rats, more so in poor prognosis animals, with a blunted inotropic response to dobutamine, indicative of SIM. Cholesterol administration restored cardiomyocyte membrane cholesterol, dobutamine responsiveness and adrenergic signaling. CONCLUSIONS: In a long-term rat model of sepsis, that parallels changes seen in septic patients, cardiomyocyte membrane cholesterol fell with associated decreases in catecholamine responsiveness. These features could be restored by cholesterol infusion, suggesting potential utility as a therapeutic.
2. Quorum-sensing control of sepsis in the coagulase-negative staphylococcal species Staphylococcus haemolyticus.
In experimental S. haemolyticus sepsis, the Agr quorum-sensing system controls mortality by regulating cytolytic PSM toxins. This establishes Agr–PSM as a tractable antivirulence target for coagulase-negative staphylococcal sepsis and highlights pathogen-specific differences from S. aureus.
Impact: Provides mechanistic evidence that quorum-sensing drives lethality in coagulase-negative staphylococcal sepsis via PSMs, opening a new therapeutic modality distinct from bactericidal approaches.
Clinical Implications: Supports development of Agr/PSM-targeted antivirulence agents for catheter-related and nosocomial bloodstream infections due to coagulase-negative staphylococci; emphasizes species-specific precision in anti-virulence therapy.
Key Findings
- Agr quorum-sensing strongly impacted mortality in experimental S. haemolyticus sepsis.
- Agr tightly regulates phenol-soluble modulins (PSMs), with cytolytic PSM activity underlying lethality.
- Antivirulence targeting of Agr/PSM is promising for coagulase-negative staphylococcal sepsis, contrasting S. aureus.
Methodological Strengths
- In vivo sepsis mortality model with genetic dissection of quorum-sensing pathways
- Mechanistic linkage of Agr signaling to PSM toxin function
Limitations
- Preclinical animal study; human translational validation is lacking
- Findings may be species- and strain-specific and not generalizable to all coagulase-negative staphylococci
Future Directions: Develop and test Agr/PSM inhibitors in relevant device-associated infection models and assess synergy with antibiotics; evaluate safety and resistance evolution.
Quorum sensing is often proposed as a target for antivirulence drug development against bacterial pathogens. Coagulase-negative staphylococci are leading causes of nosocomial blood infections and associated mortality. However, there is a severe lack of understanding how virulence and quorum sensing affect coagulase-negative staphylococcal sepsis. We show that the Agr quorum-sensing system has a strong impact on mortality from experimental sepsis caused by the exemplary coagulase-negative staphylococcal species Staphylococcus haemolyticus. This was based on strict Agr regulation of phenol-soluble modulin (PSM) toxins with PSM cytolytic capacity predominantly underlying the observed effect. These findings imply that Agr and PSMs represent promising targets for antivirulence drug development targeting sepsis caused by coagulase-negative staphylococci. This contrasts S. aureus blood infections, for which such approaches are considered less promising-a difference our results suggest is due to the PSM-focused mode of Agr control in coagulase-negative staphylococci.
3. Examining Transcriptomic Markers Associated With Neutrophil Extracellular Traps to Predict Mortality Risk in Neonatal Sepsis.
A NETs-derived transcriptomic score built from whole blood of 123 neonates with sepsis predicted adverse outcomes with high accuracy (AUC ~0.85–0.89) across validation cohorts. Mediation and temporal analyses support a mechanistic link wherein NETosis precedes and promotes coagulopathy.
Impact: Introduces a validated, biologically anchored risk score for neonatal sepsis and clarifies the NETosis–coagulation axis, enabling precision selection for targeted therapies.
Clinical Implications: Supports early molecular risk stratification to identify neonates at risk for sepsis-associated coagulopathy and mortality, informing enrollment in trials of anticoagulant or anti-NET interventions.
Key Findings
- A NET gene-based score predicted adverse outcomes in neonatal sepsis with AUCs of 88.7% and 85.4% in two validation cohorts.
- Mediation and temporal analyses supported a sequential link between NETosis and coagulopathy.
- Age-specificity analyses indicated the model’s neonatal relevance compared with pediatric/adult data.
Methodological Strengths
- Derivation and validation across independent cohorts with strong discrimination metrics
- Mediation and temporal analyses anchoring the biology of NETosis–coagulation
Limitations
- Generalizability beyond studied cohorts and clinical implementation pathways remain to be established
- Transcriptomic assays may face logistical constraints; external prospective validation is needed
Future Directions: Prospective multicenter validation and interventional studies enriching high NET score neonates for targeted anti-coagulant/anti-NET therapies.
BACKGROUND: Neonates are highly susceptible to sepsis, which is often accompanied by fatal coagulopathy. Anticoagulant therapies have not reduced sepsis-related mortality in clinical trials, possibly due to patient heterogeneity. Neutrophil extracellular traps (NETs) enhance coagulation by activating platelets, suggesting that NET-specific biomarkers may identify patients who may benefit from targeted anticoagulant treatment. This study evaluated the association between NET gene expression and adverse outcomes in neonatal sepsis. METHODS: We analyzed whole blood transcriptomes from 123 neonates with sepsis and developed a predictive model, the NET score, based on NET-related gene expression. Model performance was assessed in two independent validation sets. Mediation and correlation analyses explored the relationship between the NET score and a coagulation score. Temporal transcriptomic data from septic shock cases further tested this interaction. RESULTS: The NET score achieved AUCs of 88.7% and 85.4% in validation Sets 1 and 2, respectively, indicating strong predictive performance. Mediation and temporal analyses supported a sequential relationship between NETosis and coagulation in sepsis. Age-specificity of the model was confirmed using pediatric ( CONCLUSIONS: Our findings support a novel risk stratification approach using the NET score to identify neonates at increased risk for sepsis-associated coagulopathy and poor outcomes, potentially guiding targeted therapeutic strategies.